Hematuria News and Research

RSS
In medicine, hematuria, or haematuria, is the presence of red blood cells (erythrocytes) in the urine. It may be idiopathic and/or benign, or it can be a sign that there is a kidney stone or a tumor in the urinary tract (kidneys, ureters, urinary bladder, prostate, and urethra), ranging from trivial to lethal.
Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

NeoTract presents new clinical data from studies of UroLift System for patients with BPH

NeoTract presents new clinical data from studies of UroLift System for patients with BPH

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

NeoTract announces results of study measuring costs and patient outcomes of UroLift System

NeoTract announces results of study measuring costs and patient outcomes of UroLift System

AUA recommends use of UroLift System for managing lower urinary tract symptoms attributed to BPH

AUA recommends use of UroLift System for managing lower urinary tract symptoms attributed to BPH

New article explores cost-effectiveness of initial diagnostic protocols for microscopic hematuria

New article explores cost-effectiveness of initial diagnostic protocols for microscopic hematuria

Pacific Edge announces commercial launch of Cxbladder Monitor in the U.S.

Pacific Edge announces commercial launch of Cxbladder Monitor in the U.S.

World Kidney Day 2016 focuses on children

World Kidney Day 2016 focuses on children

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes  in CLL/SLL patients

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting